7. Literatur

1. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med. 2002; 347:643-52.
2. Forster-Waldl E, Sadeghi K, Tamandl D, Gerhold B, Hallwirth U, Rohrmeister K, et al. Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res. 2005; 58:121-4 Epub 2005 May 5.
3. Gotoff S. Infections of the Neonatal Infant. In: Richard E. Behrmann RMK, Hal B Jenson, editor. Nelson Textbook of Pediatrics. Philadelphia: W.B. Saunders Company; 2000. p. 538-43.
4. Ahrens P, Kattner E, Kohler B, Hartel C, Seidenberg J, Segerer H, et al. Mutations of genes involved in the innate immune system as predictors of sepsis in very low birth weight infants. Pediatr Res 2004; 55:652-6. Epub 2004 Jan 22.
5. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. Jama. 2001; 285:1316-21.
6. Gordon AC, Waheed U, Hansen TK, Hitman GA, Garrard CS, Turner MW, et al. Mannose-Binding Lectin Polymorphisms in Severe Sepsis: Relationship to Levels, Incidence, and Outcome. Shock. 2006; 25:88-93.
7. Lau YL, Chan SY, Turner MW, Fong J, Karlberg J. Mannose-binding protein in preterm infants: developmental profile and clinical significance. Clin Exp Immunol. 1995; 102:649-54.
8. Saevarsdottir S, Vikingsdottir T, Valdimarsson H. The potential role of mannan-binding lectin in the clearance of self-components including immune complexes. Scand J Immunol 2004; 60:23-9.
9. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol 2001; 38:133-49.
10. Dean MM, Minchinton RM, Heatley S, Eisen DP. Mannose binding lectin acute phase activity in patients with severe infection. J Clin Immunol 2005; 25:346-52.
11. Klein NJ. Mannose-binding lectin: do we need it? Mol Immunol 2005; 42:919-24 Epub 2005 Jan 26.
12. Presanis JS, Kojima M, Sim RB. Biochemistry and genetics of mannan-binding lectin (MBL). Biochem Soc Trans 2003; 31:748-52.
13. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev. 2001; 180:86-99.
14. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol. 2003; 40:423-9.
15. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today. 1996; 17:532-40.
16. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003; 37:1496-505. Epub 2003 Nov 6.

17. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349:236-40.
18. Saifuddin M, Hart ML, Gewurz H, Zhang Y, Spear GT. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol. 2000; 81:949-55.
19. Kase T, Suzuki Y, Kawai T, Sakamoto T, Ohtani K, Eda S, et al. Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology. 1999; 97:385-92.
20. Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ, Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun. 2000; 68:688-93.
21. van Emmerik LC, Kuijper EJ, Fijen CA, Dankert J, Thiel S. Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin Exp Immunol. 1994; 97:411-6.
22. Kilpatrick DC. Mannan-binding lectin and its role in innate immunity. Transfus Med. 2002; 12:335-52.
23. Casanova JL, Abel L. Human Mannose-binding Lectin in Immunity: Friend, Foe, or Both? J Exp Med. 2004; 199:1295-9.
24. Garred P, Madsen HO, Halberg P, Petersen J, Kronborg G, Svejgaard A, et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum. 1999; 42:2145-52.
25. Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, Summerfield JA, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet. 1992; 1:709-15.
26. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999; 353:1049-53.
27. Graudal NA, Homann C, Madsen HO, Svejgaard A, Jurik AG, Graudal HK, et al. Mannan binding lectin in rheumatoid arthritis. A longitudinal study. J Rheumatol. 1998; 25:629-35.
28. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods. 2000; 241:33-42.
29. Turner MW, Hamvas RM. Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet. 2000; 2:305-22.
30. Lipscombe RJ, Sumiya M, Summerfield JA, Turner MW. Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. Immunology. 1995; 85:660-7.
31. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol. 1998; 161:3169-75.
32. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet. 1989; 2:1236-9.

33. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. Bmj. 1997; 314:1229-32.
34. Obladen M. Infektionen. In: Obladen M, Maier RF, editors. Neugeborenenintensivmedizin. 7th ed. Heidelberg: Springer Medizin Verlag; 2006. p. 517-45.
35. Ballow M, Cates KL, Rowe JC, Goetz C, Desbonnet C. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res. 1986; 20:899-904.
36. Kapur R, Yoder MC, Polin RA. The Immune System/ Part One: Developmental Immunology. In: Avroy A. Fanaroff RJM, editor. Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. 7th ed: Mosby; 2001. p. 676-706.
37. Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001; 358:614-8.
38. Garred P, Madsen HO. Genetic Susceptibility to Sepsis: A Possible Role for Mannose-binding Lectin. Curr Infect Dis Rep 2004; 6:367-73.
39. Garred P, J JS, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003; 188:1394-403. Epub 2003 Oct 15.
40. Fidler KJ, Wilson P, Davies JC, Turner MW, Peters MJ, Klein NJ. Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Med. 2004; 30:1438-45 Epub 2004 May 4.
41. Kilpatrick DC. Introduction to mannan-binding lectin. Biochem Soc Trans. 2003; 31:745-7.
42. Gastmeier P, Geffers C, Schwab F, Fitzner J, Obladen M, Ruden H. Development of a surveillance system for nosocomial infections: the component for neonatal intensive care units in Germany. J Hosp Infect. 2004; 57:126-31.
43. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002; 110:285-91.
44. Auriti C, Maccallini A, Di Liso G, Di Ciommo V, Ronchetti MP, Orzalesi M. Risk factors for nosocomial infections in a neonatal intensive-care unit. J Hosp Infect. 2003; 53:25-30.
45. Edwards WH. Preventing nosocomial bloodstream infection in very low birth weight infants. Semin Neonatol. 2002; 7:325-33.
46. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004; 17:638-80.
47. Robert-Koch-Institut. Krankenhaus-Infektions-Surveillance-System (KISS), NEO-KISS: Surveillance-Protokoll neonatalogische Intensivpatienten. Berlin, 2004.
48. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Semin Perinatol. 2003; 27:293-301.
49. Devlin LA, Lassiter HA. Immunoenhancement to prevent nosocomial coagulase-negative staphylococcal sepsis in very low-birth-weight infants. Clin Perinatol. 2004; 31:69-75.

50. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. 2002; 347:240-7.
51. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J. 1998; 17:593-8.
52. Belohradsky BH, Scholz H. Sepsis. In: (DGPI) DGfpIeV, editor. Handbuch Infektionen bei Kindern und Jugendlichen. München: Futuramed Verlag, München; 2000. p. 797-804.
53. Kühl PG. Neonatalogie, Infektionen des Neugeborenen, Sepsis. In: Dr. S. Illing DMCe, editor. Klinikleitfaden Pädiatrie. München, Jena: Urban & Fischer; 2003. p. 168-9.
54. Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am. 1996; 43:409-32.
55. Reber KM, Nankervis CA. Necrotizing enterocolitis: preventative strategies. Clin Perinatol. 2004; 31:157-67.
56. Kliegman RM, Walker WA, Yolken RH. Necrotizing enterocolitis: research agenda for a disease of unknown etiology and pathogenesis. Pediatr Res. 1993; 34:701-8.
57. Holman RC, Stoll BJ, Clarke MJ, Glass RI. The epidemiology of necrotizing enterocolitis infant mortality in the United States. Am J Public Health. 1997; 87:2026-31.
58. Caplan MS, Jilling T. New concepts in necrotizing enterocolitis. Curr Opin Pediatr. 2001; 13:111-5.
59. Lee JS, Polin RA. Treatment and prevention of necrotizing enterocolitis. Semin Neonatol. 2003; 8:449-59.
60. Turner MA, Power S, Emmerson AJ. Gestational age and the C reactive protein response. Arch Dis Child Fetal Neonatal Ed. 2004; 89:F272-3.
61. Ng PC. Diagnostic markers of infection in neonates. Arch Dis Child Fetal Neonatal Ed. 2004; 89:F229-35.
62. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991; 115:457-69.
63. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997; 112:235-43.
64. Del Vecchio A, Laforgia N, Capasso M, Iolascon A, Latini G. The role of molecular genetics in the pathogenesis and diagnosis of neonatal sepsis. Clin Perinatol. 2004; 31:53-67.
65. Medzhitov R, Janeway CA, Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 2002; 296:298-300.
66. Hill HR, Bohnsack JF, La Pine TR. The Natural (Innate) Defense System. In: E. Richard Stiem HDO, Jerry A Winkelstein, editor. Immunologic Disorders in Infants and Children. Philedelphia: Elsevier Saunders; 2004. p. 245-64.
67. Liu H, Jensen L, Hansen S, Petersen SV, Takahashi K, Ezekowitz AB, et al. Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. Scand J Immunol. 2001; 53:489-97.

68. Windbichler M, Echtenacher B, Hehlgans T, Jensenius JC, Schwaeble W, Mannel DN. Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis. Infect Immun 2004; 72:5247-52.
69. Braun M, Eppinger T, Renz-Polster H. Immunsystem. In: Renz-Polster H, Braun J, editors. Basislehrbuch Innere Medizin. 2nd ed. München, Jena: Urban & Fischer Verlag; 2001. p. 326-91.
70. Stern CM. Neonatal Infection, Neonatal Immunology. In: J.M. Rennie NRCR, editor. Textbook of Neonatology. Edinburgh: Churchill Livingstone; 1999. p. 1093-107.
71. Lewis DB. The Physiologic Immunodeficiency of Immaturity. In: E. Richard Stiem HDO, Jerry A Winkelstein, editor. Immunologic Disorders in Infants and Children. Philadelphia: Elsevier Saunders; 2004. p. 688-740.
72. Bellanti JA, Pung Y-H, Zeligs BJ. Immunology. In: Gordon B. Avery MAF, Mhairi G. Macdonald, editor. Neonatology, Pathophysiology and Management of the Newborn. Philedelphia: J. B. Lippincott Company; 1994. p. 1000-25.
73. Fujita T, Endo Y, Nonaka M. Primitive complement system--recognition and activation. Mol Immunol. 2004; 41:103-11.
74. Carcillo JA. Mannose-binding lectin deficiency provides a genetic basis for the use of SIRS/sepsis definitions in critically ill patients. Intensive Care Med 2004; 30:1263-5. Epub 2004 May 6.
75. Harmat V, Gal P, Kardos J, Szilagyi K, Ambrus G, Vegh B, et al. The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme-substrate interactions. J Mol Biol. 2004; 342:1533-46.
76. Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001; 358:637-8.
77. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway--its role in innate immunity and evolution. Immunol Rev. 2004; 198:185-202.
78. Müller-Hilke B. Überempfindlichkeit und Autoimmunität. 2006: WWW-Seite. Internet: http://www.iimmun.med.uni-rostock.de/pdf/05_15.05.6.pdf (Zugriff: 2.2.2007, 15.35 MEZ).
79. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997; 386:506-10.
80. Dahl MR, Thiel S, Matsushita M, Fujita T, Willis AC, Christensen T, et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity. 2001; 15:127-35.
81. Berger M, Frank MM. The Serum Complement System. In: E. Richard Stiem HDO, Jerry A Winkelstein, editor. Immunologic Disorders in Infants and Children. Philedelphia: Elsevier Saunders; 2004. p. 157-82.
82. Johnston RBJ. The Complement System. In: Richard E. Behrmann RMK, Hal B Jenson, editor. Nelson Textbook of Pediatrics. Philadelphia: W.B. Saunders Company; 2000. p. 628-34.
83. Ezekowitz RA. Role of the mannose-binding lectin in innate immunity. J Infect Dis. 2003; 187:S335-9.

84. De Maio A, Torres MB, Reeves RH. Genetic determinants influencing the response to injury, inflammation, and sepsis. Shock 2005; 23:11-7.
85. Dahmer MK, Randolph A, Vitali S, Quasney MW. Genetic polymorphisms in sepsis. Pediatr Crit Care Med 2005; 6:S61-73.
86. Jack DL, Read RC, Tenner AJ, Frosch M, Turner MW, Klein NJ. Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J Infect Dis. 2001; 184:1152-62 Epub 2001 Sep 26.
87. Gastmeier P, Geffers C, Brandt C, Zuschneid I, Sohr D, Schwab F, et al. Effectiveness of a nationwide nosocomial infection surveillance system for reducing nosocomial infections. J Hosp Infect. 2006; 64:16-22 Epub 2006 Jul 3.
88. Gastmeier P, Daschner F, Henning R. Reduktion nosokomialer Infektionen durch Surveillance. Deutsches Ärzteblatt 102 2005:C1674-77.
89. Gastmeier P, Hentschel J, de Veer I, Obladen M, Ruden H. Device-associated nosocomial infection surveillance in neonatal intensive care using specified criteria for neonates. J Hosp Infect 1998; 38:51-60.
90. Frakking FN, Brouwer N, Zweers D, Merkus MP, Kuijpers TW, Offringa M, et al. High prevalence of mannose-binding lectin (MBL) deficiency in premature neonates. Clin Exp Immunol. 2006; 145:5-12.
91. Hilgendorff A, Schmidt R, Bohnert A, Merz C, Bein G, Gortner L. Host defence lectins in preterm neonates. Acta Paediatr. 2005; 94:794-9.
92. Terai I, Kobayashi K. Perinatal changes in serum mannose-binding protein (MBP) levels. Immunol Lett. 1993; 38:185-7.
93. Aittoniemi J, Miettinen A, Laippala P, Isolauri E, Viikari J, Ruuska T, et al. Age-dependent variation in the serum concentration of mannan-binding protein. Acta Paediatr. 1996; 85:906-9.
94. Thiel S, Bjerke T, Hansen D, Poulsen LK, Schiotz PO, Jensenius JC. Ontogeny of human mannan-binding protein, a lectin of the innate immune system. Pediatr Allergy Immunol. 1995; 6:20-3.
95. Innate Immunity in Heart, Lung and Blood Disease/Programs for Genomic Applications. WWW-Seite. Internet: http://www.innateimmunity.net (Zugriff: 03.2.2007, 09.49 MEZ).
96. van der Zwet WC, Kaiser AM, van Elburg RM, Berkhof J, Fetter WP, Parlevliet GA, et al. Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. J Hosp Infect. 2005; 61:300-11 Epub 2005 Oct 10.
97. Brodie SB, Sands KE, Gray JE, Parker RA, Goldmann DA, Davis RB, et al. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units. Pediatr Infect Dis J. 2000; 19:56-65.
98. Luig M, Lui K. Epidemiology of necrotizing enterocolitis--Part II: Risks and susceptibility of premature infants during the surfactant era: a regional study. J Paediatr Child Health. 2005; 41:174-9.
99. Gibbs K, Lin J, Holzman IR. Necrotising enterocolitis: the state of the science. Indian J Pediatr. 2007; 74:67-72.

100. Kosloske AM. Epidemiology of necrotizing enterocolitis. Acta Paediatr Suppl. 1994; 396:2-7.
101. Baltimore RS. Neonatal sepsis: epidemiology and management. Paediatr Drugs. 2003; 5:723-40.
102. Lott JW. Neonatal bacterial sepsis. Crit Care Nurs Clin North Am. 2003; 15:35-46.
103. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med. 2002; 30:969-73.
104. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med. 2002; 162:1028-32.
105. Kilpinen S, Hulkkonen J, Wang XY, Hurme M. The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw. 2001; 12:62-8.
106. Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33:638-44.
107. Mullighan CG, Heatley S, Doherty K, Szabo F, Grigg A, Hughes TP, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood. 2002; 99:3524-9.
108. Mullighan CG, Bardy PG. Mannose-binding lectin and infection following allogeneic hemopoietic stem cell transplantation. Leuk Lymphoma. 2004; 45:247-56.
109. Garred P, Richter C, Andersen AB, Madsen HO, Mtoni I, Svejgaard A, et al. Mannan-binding lectin in the sub-Saharan HIV and tuberculosis epidemics. Scand J Immunol. 1997; 46:204-8.
110. Nielsen SL, Andersen PL, Koch C, Jensenius JC, Thiel S. The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients. Clin Exp Immunol. 1995; 100:219-22.
111. Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol Immunol. 2005; 42:145-52.
112. Senaldi G, Davies ET, Mahalingam M, Lu J, Pozniak A, Peakman M, et al. Circulating levels of mannose binding protein in human immunodeficiency virus infection. J Infect. 1995; 31:145-8.
113. Tsutsumi A, Takahashi R, Sumida T. Mannose binding lectin: genetics and autoimmune disease. Autoimmun Rev 2005; 4:364-72. Epub 2005 Apr 13.
114. Garred P, Madsen HO, Svejgaard A, Michaelsen TE. Mannose-binding lectin and meningococcal disease. Lancet. 1999; 354:336; author reply 7.
115. Garred P, Michaelsen TE, Bjune G, Thiel S, Svejgaard A. A low serum concentration of mannan-binding protein is not associated with serogroup B or C meningococcal disease. Scand J Immunol. 1993; 37:468-70.
116. Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet. 2002; 359:1569-73.
117. Kronborg G, Weis N, Madsen HO, Pedersen SS, Wejse C, Nielsen H, et al. Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients. J Infect Dis 2002; 185:1517-20. Epub 2002 Apr 23.

118. Shi L, Takahashi K, Dundee J, Shahroor-Karni S, Thiel S, Jensenius JC, et al. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med. 2004; 199:1379-90.
119. Vitali SH, Randolph AG. Assessing the quality of case-control association studies on the genetic basis of sepsis. Pediatr Crit Care Med. 2005; 6:S74-7.
120. Kabesch M, Schedel M, Carr D, Woitsch B, Fritzsch C, Weiland SK, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol. 2006; 117:269-74.
121. Nickel RG, Willadsen SA, Freidhoff LR, Huang SK, Caraballo L, Naidu RP, et al. Determination of Duffy genotypes in three populations of African descent using PCR and sequence-specific oligonucleotides. Hum Immunol. 1999; 60:738-42.
122. Le Souef PN, Goldblatt J, Lynch NR. Evolutionary adaptation of inflammatory immune responses in human beings. Lancet. 2000; 356:242-4.
123. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA). Nat Genet. 1997; 15:389-92.
124. Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, et al. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol. 2002; 33:201-7.